Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Agios Pharmaceuticals Says It Is Aware Of The Securities Analyst Report Published On August 4, 2025, Detailing Recent PYRUKYND Data From The U.S. FDA Adverse Event Reporting System; Co. Is Committed To Delivering Safe, Effective Treatments For Patients With Rare Diseases, And Will Continue To Follow Our Established, Rigorous Pharmacovigilance Processes; Separately, On August 4, 2025, The Saudi Food And Drug Authority Announced That It Has Approved PYRUKYND

Author: Benzinga Newsdesk | August 04, 2025 02:53pm

-SEC Filing

Posted In: AGIO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist